鉴定和验证与阿尔茨海默氏病中低氧微环境相关的基因
Mingyang Yuan1, Yanjin Feng1, Mingri Zhao2
1The Third Xiangya Hospital, Department of Neurology, Central South University, Changsha, 410000, China.
Scientific reports
|September 27, 2023
概括
与缺氧相关的基因可能会增加阿尔茨海默病 (AD) 的风险. 这项研究确定了ANTXR2,BDNF和NFKBIA等关键基因,使用生物信息学方法建立了AD的潜在诊断模型.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 生物信息学是一种生物信息学.
背景情况:
- 阿尔茨海默氏病 (AD) 发病率正在上升,越来越多的证据将缺氧与AD病原体联系起来.
- 以前的研究已经探索了AD中的反应性氧物种,神经炎症和自,但缺氧特异性基因的作用仍未得到充分研究.
- 生物信息学方法尚未广泛应用于研究缺氧和AD之间的联系.
研究的目的:
- 为了确定与低氧相关的基因与阿尔茨海默病有关.
- 评估这些低氧相关基因在AD的诊断意义.
- 开发一种基于生物信息学的AD诊断模型.
主要方法:
- 在GSE33000数据集上的差异基因表达分析和集群分析确定了7681个差异表达基因 (DEG).
- 权重基因共同表达网络分析 (WGCNA) 揭示了9个模块和205个枢纽基因.
- 使用机器学习算法来选择关键基因,然后进行外部数据集验证和qRT-PCR以建立模型.
主要成果:
- 总共有7681个DEG被确定,WGCNA突出显示了205个枢纽基因.
- 机器学习确定了四个关键基因,从而建立了使用ANTXR2,BDNF和NFKBIA的诊断模型.
- 开发的模型显示了AD诊断的潜力.
结论:
- 与缺氧相关的基因被认为会增加患阿尔茨海默病的风险.
- 已识别的基因ANTXR2,BDNF和NFKBIA形成了AD的潜在诊断特征.
- 需要进一步的研究来阐明缺氧和阿尔茨海默病之间的确切联系,这项研究为未来的研究提供了基础.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.0K
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
886
相关概念视频
Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
